利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

66 条记录 (耗时 0.034 秒)

    Predicting response to chemotherapy using gene expression markers
    31.
    发明授权
    Predicting response to chemotherapy using gene expression markers 有权
    使用基因表达标志物预测化疗反应

    公开(公告)号：US07930104B2

    公开(公告)日：2011-04-19

    申请号：US11267769

    申请日：2005-11-04

    申请人： Joffre B. Baker ,  John L. Bryant ,  Soonmyung Paik ,  Steven Shak

    发明人： Joffre B. Baker ,  John L. Bryant ,  Soonmyung Paik ,  Steven Shak

    IPC分类号： C12Q1/68 ,  G01N33/48 ,  G06G7/58

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G06F19/18 ,  G06F19/20

    摘要： The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.

    摘要翻译： 本发明提供了可用于预测癌症患者是否可能对化疗治疗具有有益反应的基因表达信息，包括在包含从患者获得的乳腺肿瘤样品的生物样品中测量基因亚群的表达水平 获得与化疗有益反应的可能性相关的风险评分，其中所述评分包括以下变量中的至少一个：（i）复发评分，（ii）ESRI组评分; （iii）入侵小组得分; （iv）增殖组得分; 和（v）MYBL2和SCUBE2中的至少一种的RNA转录物的表达水平或相应的表达产物。 本发明还包括基于分子测定的算法来计算患者将基于风险评分对化学疗法有益的反应的可能性。

    Gene expression markers for predicting response to chemotherapy
    32.
    发明授权
    Gene expression markers for predicting response to chemotherapy 有权
    用于预测化疗反应的基因表达标志物

    公开(公告)号：US07871769B2

    公开(公告)日：2011-01-18

    申请号：US11102228

    申请日：2005-04-07

    申请人： Joffre B. Baker ,  Steven Shak ,  Luca Gianni

    发明人： Joffre B. Baker ,  Steven Shak ,  Luca Gianni

    IPC分类号： C12Q1/68 ,  G01N33/53 ,  C12P19/34 ,  C07H21/04

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  Y10S435/96

    摘要： The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.

    摘要翻译： 本发明提供了一组基因，其表达在癌症的预后中是重要的。 具体地，本发明提供了可用于预测癌症患者是否可能对化疗FHIT有有益治疗反应的基因表达信息; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; 肝素 AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1，BCL2，ESR1; 或相应的表达产物，所述报告包括所述受试者具有降低的化疗反应可能性的预测。

    Molecular Indicators of Breast Cancer Prognosis and Prediction of Treatment Response
    33.
    发明申请
    Molecular Indicators of Breast Cancer Prognosis and Prediction of Treatment Response 审中-公开
    乳腺癌预后分析指标及治疗反应预测

    公开(公告)号：US20100184041A1

    公开(公告)日：2010-07-22

    申请号：US12576898

    申请日：2009-10-09

    申请人： Joffre B. Baker ,  John L. Bryant ,  Soonmyung Paik ,  Steven Shak

    发明人： Joffre B. Baker ,  John L. Bryant ,  Soonmyung Paik ,  Steven Shak

    IPC分类号： C12Q1/68

    CPC分类号： G01N33/57415 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  G16B20/00 ,  G16B25/00

    摘要： The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy.

    摘要翻译： 本发明涉及可以指导乳腺癌临床决定的定量分子指标，如雌激素受体（ESR1）阳性，淋巴结阴性乳腺癌。 特别地，本发明涉及某些基因，其变化的表达指示在佐剂设置中未用治疗剂治疗的患者中手术切除的乳腺癌复发的可能性。 此外，本发明还涉及使用量测所测量的某些基因（包括ESR1基因）的表达作为连续变量来确定（a）对抗雌激素治疗剂的有益反应的可能性，例如 作为他莫昔芬; 和（b）对化学疗法的有益反应的潜在程度。

    Genes involved in estrogen metabolism
    40.
    发明授权
    Genes involved in estrogen metabolism 有权
    参与雌激素代谢的基因

    公开(公告)号：US08808994B2

    公开(公告)日：2014-08-19

    申请号：US12972148

    申请日：2010-12-17

    申请人： Michael C. Kiefer ,  Joffre B. Baker ,  James Hackett

    发明人： Michael C. Kiefer ,  Joffre B. Baker ,  James Hackett

    IPC分类号： C12Q1/68 ,  C12P19/32

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118

    摘要： The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.

    摘要翻译： 本发明涉及已被鉴定为参与雌激素代谢的基因，并且可用作癌症中的诊断，预后和/或预测标记。 特别地，本发明涉及其肿瘤表达水平可用于诊断与雌激素代谢相关的癌症和/或临床结果的预后和/或这种癌症的药物反应预测的基因。